

Product Data Sheet

Product Name: Cobolimab

Cat. No.: GC74599

Chemical Properties

Cas. No. 2022215-65-0

Formula M.Wt

Solubility Storage

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Cobolimab

Background

Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC).

Cobolimab (0.0001-10 nM; 3 d) promotes TIM-3 internalization in a dose dependent manner in pre-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

activated T cells with an IC₅₀ value of 0.4464 nM[3]. Cobolimab (20 µg/mL; 24 h) significantly increases CD8⁺ T cell content by inhibiting TIM-3[4].

References:

- [1]. Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022. [2]. Markham A. Dostarlimab: First Approval. *Drugs*. 2021 Jul;81(10):1213-1219.
- [3]. Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. *Antib Ther*. 2020 Nov 9;3(4):227-236.
- [4]. Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. *Ann Transl Med*. 2021 Sep;9(18):1447.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA